Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Practical management of advanced mCRPC: Summary of key data and guideline recommendations

Axel Merseburger

15 Practical management of advanced mCRPC: Summary of key data and guideline recommendations

Management of advanced metastatic castration resistant prostate cancer (mCRPC) has dramatically changed. Professor Axel Merseburger, University Hospital Schleswig-Holstein, Lübeck, highlights the most important studies on which the second-line treatment options of the EAU guidelines 2016 are based on. He presents the data for overall survival and adverse effects for docetaxel, cabazitaxel (TROPIC study), abiraterone/prednisone (COU-AA-301), enzalutamide (AFFIRM) and radium-223 (ALSYMPCA). Data for combination options, sequencing strategies and prevalence of AR-V7 to predict treatment response are presented.